The prevention of cancer and development of more effective strategies to detect precursors and early-stage cancers, when treatment may be most effective, remain critical societal goals.
The 2020 Bionow Oncology Conference will present the problems that we face with prevention and early diagnosis and discuss the latest advances to address these challenges and translate the science into better care for the cancer patient. In addition to leading experts we will also hear about this challenge from the patient’s perspective.
Cancer is always a complex question and there are no simple answers which is why it’s important to hear from those at the cutting edge of developments.
Geoff Davison, CEO, Bionow
Allan Jordan, Director - Oncology Drug Discovery, Sygnature Discovery
Chair: Jonathan Perkins, Associate Director Personalised Healthcare, QIAGEN
Speakers
Alexis Webb, Research Programme Manager – Early Detection, Cancer Research UK
Andy Chaloner, CEO, Stream Bio
Sameer Kothari, Chief Executive Director, Zilico
​Will Dracup, CEO, Early Diagnostics Institute
Emily Lam, Public & Patient Involvement, The Clatterbridge Cancer Centre
Chair: Peter Simpson, Chief Scientific Officer, Medicines Discovery Catapult
Richard Weaver, Senior Vice President - Pre-Clinical Development, Sygnature Discovery
Robert Falconer, Professor of Medicinal Chemistry and Deputy Director Institute of Cancer Therapeutics, Bradford University
George Orphanides, Oncology Project Leader, Alderley Park
Chair: Jane Kendrew, Director of Translational Oncology, Sygnature Discovery
Speakers
Kim Rockley, Research Scientist, ApconiX
Juliana Maynard, Lead Scientist, Medicines Discovery Catapult
Caroline Phillips, Head of Oncology, Redx Pharma
Geoff Davison, CEO, Bionow
Alastair Richards, CEO, North West Cancer Research
Chair: Paul Stott, CEO, Seda Pharmaceutical Development Services
Speakers
Mike Frodsham, Chief Technical Officer, Quay Pharma
Claire Patterson, Senior Principal Scientist, Seda Pharmaceutical Development Services
Alyn McNaughton, Technical Director, Lonza Group
Lyn Daintree, Development Director, Crystec Pharma
Iain Armstrong, Partner, HGF
Chair: Claire Thompson, CEO, Agility Health
Panel Members
Steve McConchie, CEO, Aptus Clinical
David Howat, Director of Medtech & Therapeutic Development, Stream Bio
Allan Jordan, Director - Oncology Drug Discovery, Sygnature Discovery
Ajay Mistry, CEO, Oppilotech
Registration will open shortly. For any further queries please contact info@bionow.co.uk
Each Company Showcase Package will consist of:-
Please click HERE to view the Company Showcase Guidelines